Herpes Zoster Rates in a Large Cohort of Patients With Systemically Treated Psoriasis
Herpes zoster (HZ) is caused by reactivation of latent varicella zoster virus (VZV). Risk increases with waning cell-mediated immunity secondary to advanced age and immunosuppression. Some of the systemic agents used in moderate-to-severe psoriasis may be associated with increased HZ risk, though studies are conflicting, and data among patients with psoriasis is lacking. 1 In patients with systemically treated psoriasis, the association between medication use and HZ risk remains poorly characterized, especially with regard to biologic vs nonbiologic therapy. This study aimed to estimate HZ incidence rates (IR) among systemically treated patients with psoriasis, comparing patients treated with biologic vs nonbiologic agents, in a community-based health care delivery setting. Results | Cohort members were followed for a mean of 5.3 person-years. Nonbiologic users were older than biologic users, and women were less likely to have used biologics (Table 1) .
Of the 5889 participants with systemically treated psoriasis, 291 had HZ diagnosed during follow-up. Crude IRs showed that, compared with those on no systemic therapy at the time of HZ diagnosis (IR, 8.6; 95% CI, 7.1-10.0), those on systemic therapy had a statistically nonsignificant increased HZ risk (IR, 10.2; 95% CI, 8.6-11.8; P= .14) ( Table 2) . After adjusting for age and sex, there were no significant differences between those receiving no systemic therapy (aIR, 6.1; 95% CI, 4.1-8.1), any systemic therapy (aIR, 8.1; 95% CI, 5.3-11.0), biologics only (aIR, 7.8; 95% CI, 4.1-11.5), nonbiologics only (aIR, 8.9; 95% CI, 4.1-13.6), or a combination therapy (aIR, 5.6; 95% CI, 1.2-10.0).
Discussion | Few studies have examined the association between systemic medication use and HZ risk in patients with (49) 1071 (47) 1843 (51) Male 2975 (51) 1187 (53) 1788 (49) Duration of psoriasis, y 2.7 (3) 3.0 (3) 2.5 (3)
Abbreviation: KPNC, Kaiser Permanente Northern California.
Letters psoriasis. [3] [4] [5] Crude point estimates did not suggest an increased HZ risk in systemically treated patients with psoriasis, and we found no significant differences in HZ risk among those exposed to biologic vs nonbiologic therapy after adjusting for age and sex.
Limitations. limitations of the study include lack of data on disease severity and potentially limited generalizability to other healthcare settings.
Conclusions | Among a cohort of patients with moderate-tosevere psoriasis who were treated with a systemic agent on cohort entry, we found no significant differences in HZ risk at time of HZ diagnosis among those treated with systemic therapy vs no systemic therapy, and among systemically treated patients, among those treated with biologics versus no biologic agents. Our results are similar to those of a recently published retrospective cohort study 4 that found no significant association between biologics as single agents and adjusted HZ risk in patients with psoriasis. We previously reported an increased risk of bacterial skin and soft tissue infections among those treated with biologics compared with those treated with nonbiologics in this cohort. 6 Biologics block the activity of cytokines such as TNF-α, which plays a role in protecting against bacterial infections and inhibiting reactivation of latent viruses. Incident rates of HZ were increased in systemically treated patients with psoriasis as compared with the general population. However, we found no significant differences in HZ risk among those exposed to biologic vs nonbiologic therapy after adjusting for age and sex. Our results suggest that among systemically treated psoriasis patients, biologics may preferentially inhibit immune mechanisms specific for bacterial defense while sparing cell-mediated immune responses specific for maintaining VZV latency.
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